High heterogeneity of fecal carriage extended-spectrum beta-lactamase-producing E. coli isolated from iranian community and clinical settings - BMC Infectious Diseases - BMC Infectious Diseases

  • Ouchar Mahamat O, Tidjani A, Lounnas M, Hide M, Benavides J, Somasse C, Ouedraogo A-S, Sanou S, Carrière C, Bañuls A-L. Fecal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae in hospital and community settings in Chad. Antimicrob Resist Infect Control. 2019;8(1):1–7.

    Article  Google Scholar 

  • Reuland E, Al Naiemi N, Kaiser A, Heck M, Kluytmans J, Savelkoul P, Elders P, Vandenbroucke-Grauls C. Prevalence and risk factors for carriage of ESBL-producing Enterobacteriaceae in Amsterdam. J Antimicrob Chemother. 2016;71(4):1076–82.

    CAS  Article  Google Scholar 

  • Aghamohammad S, Badmasti F, Solgi H, Aminzadeh Z, Khodabandelo Z, Shahcheraghi F. First report of extended-spectrum betalactamase-producing Klebsiella pneumoniae among fecal carriage in Iran: high diversity of clonal relatedness and virulence factor profiles. Microb Drug Resist. 2020;26(3):261–9.

    CAS  Article  Google Scholar 

  • Mathai D, Kumar VA, Paul B, Sugumar M, John KR, Manoharan A, Kesavan LM. Fecal carriage rates of extended-spectrum β-lactamase-producing Escherichia coli among antibiotic naive healthy human volunteers. Microb Drug Resist. 2015;21(1):59–64.

    CAS  Article  Google Scholar 

  • Kaesbohrer A, Bakran-Lebl K, Irrgang A, Fischer J, Kämpf P, Schiffmann A, Werckenthin C, Busch M, Kreienbrock L, Hille K. Diversity in prevalence and characteristics of ESBL/pAmpC producing E. coli in food in Germany. Vet Microbiol. 2019;233:52–60.

    CAS  Article  Google Scholar 

  • Zhang H, Zhou Y, Guo S, Chang W. High prevalence and risk factors of fecal carriage of CTX-M type extended-spectrum beta-lactamase-producing Enterobacteriaceae from healthy rural residents of Taian, China. Front Microbiol. 2015;6:239.

    PubMed  PubMed Central  Google Scholar 

  • Aghamohammad S, Badmasti F, Shirazi AS, Dabiri H, Solgi H, Sabeti S, Shahcheraghi F. Considerable rate of putative virulent phylo-groups in fecal carriage of extended-spectrum β-lactamase producing Escherichia coli. Infect Genet Evol. 2019;73:184–9.

    CAS  Article  Google Scholar 

  • Ghaderi RS, Yaghoubi A, Amirfakhrian R, Hashemy SI, Ghazvini K. The prevalence of genes encoding ESBL among clinical isolates of Escherichia coli in Iran: a systematic review and meta-analysis. Gene Rep. 2020;18:100562.

    Article  Google Scholar 

  • Ghotaslou R, Sadeghi MR, Akhi MT, Hasani A, Asgharzadeh M. Prevalence and antimicrobial susceptibility patterns of ESBL, ampC and carbapenemase-producing Enterobactericeae isolated from hospitalized patients in Azerbaijan, Iran. Iran J Pharm Res. 2018;17(Suppl):79.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Ny S, Löfmark S, Börjesson S, Englund S, Ringman M, Bergström J, Nauclér P, Giske CG, Byfors S. Community carriage of ESBL-producing Escherichia coli is associated with strains of low pathogenicity: a Swedish nationwide study. J Antimicrob Chemother. 2016. https://doi.org/10.1093/jac/dkw419.

    Article  PubMed  Google Scholar 

  • Johnson JR, Johnston BD, Gordon DM. Rapid and specific detection of the Escherichia coli sequence type 648 complex within phylogroup F. J Clin Microbiol. 2017;55(4):1116–21.

    CAS  Article  Google Scholar 

  • Adzitey F, Huda N, Ali GRR. Molecular techniques for detecting and typing of bacteria, advantages and application to foodborne pathogens isolated from ducks. 3 Biotech. 2013;3(2):97–107.

    Article  Google Scholar 

  • Malekzadegan Y, Amanati A, Bazargani A, Ramzi M, Motamedifar M. Fecal colonization, phenotypic and genotypic characterization of ESBL-producing Escherichia coli isolates in transplant patients in Shiraz Nemazee and Abu Ali Sina Hospitals. Gene Rep. 2021;25:101321.

    Article  Google Scholar 

  • Solgi H, Badmasti F, Aminzadeh Z, Giske C, Pourahmad M, Vaziri F, Havaei S, Shahcheraghi F. Molecular characterization of intestinal carriage of carbapenem-resistant Enterobacteriaceae among inpatients at two Iranian university hospitals: first report of co-production of bla NDM-7 and bla OXA-48. Eur J Clin Microbiol Infect Dis. 2017;36(11):2127–35.

    CAS  Article  Google Scholar 

  • Huang SW, Chang CH, Tai TF, Chang TC. Comparison of the β-glucuronidase assay and the conventional method for identification of Escherichia coli on eosin-methylene blue agar. J Food Protect. 1997;60(1):6–9.

    CAS  Article  Google Scholar 

  • Shahcheraghi F, Nobari S, Rahmati Ghezelgeh F, Nasiri S, Owlia P, Nikbin VS, Imani Fooladi AA. First report of New Delhi metallo-beta-lactamase-1-producing Klebsiella pneumoniae in Iran. Microb Drug Resist. 2013;19(1):30–6.

    CAS  Article  Google Scholar 

  • Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DH, Swaminathan B. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol. 1995;33(9):2233–9.

    CAS  Article  Google Scholar 

  • Kateregga JN, Kantume R, Atuhaire C, Lubowa MN, Ndukui JG. Phenotypic expression and prevalence of ESBL-producing Enterobacteriaceae in samples collected from patients in various wards of Mulago Hospital, Uganda. BMC Pharmacol Toxicol. 2015;16(1):1–6.

    CAS  Article  Google Scholar 

  • Aris P, Boroumand MA, Rahbar M, Douraghi M. The activity of fosfomycin against extended-spectrum beta-lactamase-producing isolates of Enterobacteriaceae recovered from urinary tract infections: a single-center study over a period of 12 years. Microb Drug Resist. 2018;24(5):607–12.

    CAS  Article  Google Scholar 

  • Kurz MS, Bayingana C, Ndoli JM, Sendegeya A, Durst A, Pfüller R, Gahutu JB, Mockenhaupt FP. Intense pre-admission carriage and further acquisition of ESBL‐producing Enterobacteriaceae among patients and their caregivers in a tertiary hospital in Rwanda. Trop Med Int Health. 2017;22(2):210–20.

    CAS  Article  Google Scholar 

  • Pilmis B, Cattoir V, Lecointe D, Limelette A, Grall I, Mizrahi A, Marcade G, Poilane I, Guillard T, Nicolaos NB. Carriage of ESBL-producing Enterobacteriaceae in French hospitals: the PORTABLSE study. J Hosp Infect. 2018;98(3):247–52.

    CAS  Article  Google Scholar 

  • Arcilla MS, Van Hattem JM, Bootsma MC, van Genderen PJ, Goorhuis A, Grobusch MP, Klaassen CH, Lashof AMO, Schultsz C, Stobberingh EE. Prevalence and risk factors for carriage of ESBL-producing Enterobacteriaceae in a population of Dutch travellers: a cross-sectional study. Travel Med Infect Dis. 2020;33:101547.

    Article  Google Scholar 

  • Lübbert C, Straube L, Stein C, Makarewicz O, Schubert S, Mössner J, Pletz MW, Rodloff AC. Colonization with extended-spectrum beta-lactamase-producing and carbapenemase-producing Enterobacteriaceae in international travelers returning to Germany. Int J Med Microbiol. 2015;305(1):148–56.

    Article  Google Scholar 

  • Goulenok T, Ferroni A, Bille E, Lécuyer H, Join-Lambert O, Descamps P, Nassif X, Zahar J. Risk factors for developing ESBL E. coli: can clinicians predict infection in patients with prior colonization? J Hosp Infect. 2013;84(4):294–9.

    CAS  Article  Google Scholar 

  • Nordberg V, Jonsson K, Giske C, Iversen A, Aspevall O, Jonsson B, Camporeale A, Norman M, Navér L. Neonatal intestinal colonization with extended-spectrum β-lactamase-producing Enterobacteriaceae—a 5-year follow-up study. Clin Microbiol Infect. 2018;24(9):1004–9.

    CAS  Article  Google Scholar 

  • Bezabih YM, Sabiiti W, Alamneh E, Bezabih A, Peterson GM, Bezabhe WM, Roujeinikova A. The global prevalence and trend of human intestinal carriage of ESBL-producing Escherichia coli in the community. J Antimicrob Chemother. 2021;76(1):22–9.

    CAS  Article  Google Scholar 

  • Barreto Miranda I, Ignatius R, Pfüller R, Friedrich-Jänicke B, Steiner F, Paland M, Dieckmann S, Schaufler K, Wieler LH, Guenther S. High carriage rate of ESBL-producing Enterobacteriaceae at presentation and follow-up among travellers with gastrointestinal complaints returning from India and Southeast Asia. J Travel Med. 2016;23(2):tav024.

    Article  Google Scholar 

  • Sistanizad M, Kouchek M, Miri M, Goharani R, Solouki M, Ayazkhoo L, Foroumand M, Mokhtari M. Carbapenem restriction and its effect on bacterial resistance in an intensive care unit of a teaching hospital. Iran J Pharm Res. 2013;12(3):503.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Eftekhar F, Seyedpour SM. Prevalence of qnr and aac (6′)-Ib-cr genes in clinical isolates of Klebsiella pneumoniae from Imam Hussein Hospital in Tehran. Iran J Med Sci. 2015;40(6):515.

    Google Scholar 

  • Pitart C, Solé M, Roca I, Román A, Moreno A, Vila J, Marco F. Molecular characterization of blaNDM-5 carried in an IncFII plasmid in Escherichia coli from a non-traveller patient in Spain. Antimicrob Agents Chemother. 2014;59(1):659–62.

    Article  Google Scholar 

  • Hajihasani A, Ebrahimi-Rad M, Rasoulinasab M, Aslani MM, Shahcheraghi F. Prevalence of O25b-ST131 Escherichia coli clone: fecal carriage of extended-spectrum β-lactamase and carbapenemase-producing isolates in healthy adults in Tehran, Iran. Microb Drug Resist. 2021;28(2):210–6.

    Article  Google Scholar 

  • Janvier F, Delacour H, Tesse S, Larreche S, Sanmartin N, Ollat D, Rapp C, Merens A. Faecal carriage of extended-spectrum β-lactamase-producing enterobacteria among soldiers at admission in a French military hospital after aeromedical evacuation from overseas. Eur J Clin Microbiol Infect Dis. 2014;33(10):1719–23.

    CAS  Article  Google Scholar 

    • Adblock test (Why?)

    Comments

    Post a Comment

    Popular posts from this blog

    Rashes that look like scabies: Causes, symptoms, and treatment - Medical News Today

    Image
    Scabies is a skin condition that occurs as the result of a mite known as Sarcoptes scabiei. The rash that results from scabies may appear similar to other skin conditions, such as psoriasis, eczema, or contact dermatitis. In this article, we look at what a scabies rash looks like. We also look at other rashes that are similar in appearance and their treatment options. Scabies is a common condition that occurs as the result of an infestation of a microscopic skin mite called Sarcoptes scabiei. The mites burrow under the skin, causing intense itching and a rash. The Centers for Disease Control and Prevention (CDC) describes the rash as pimple-like. On darker skin, the rash may be more difficult to see, but a person should be able to feel it. According to DermNet, a scabies rash is varied in appearance, and may appear as: pimple-like on the limbs and trunk widespread or coin-shaped small blisters scales lesions in the armpits, groin, navel, areolas, scrotum, buttocks, and along the penil
    Read more

    Urinary Tract Infection (UTI): Causes, Symptoms & Treatment - Cleveland Clinic

    Image
    Can I prevent a urinary tract infection? The following lifestyle changes can help prevent urinary tract infections: Practice good hygiene Practicing good hygiene is one of the best ways to help prevent UTIs. This is especially important if you have a vagina because your urethra is much shorter, and it's easier for E. coli to move from your rectum back into your body. Always wipe from front to back after a bowel movement (pooping) to avoid this. During your menstrual cycle, it's also a good idea to regularly change your period products, including pads and tampons. You should also avoid using any deodorants on your vagina. Drink plenty of fluids Drinking extra fluids — especially water — each day can help flush out bacteria from your urinary tract. Healthcare providers recommend drinking six to eight glasses of water daily. Change your peeing habits Peeing can play a big role in getting rid of bacteria from your body. Your pee is a waste product, and each time you empty your bla
    Read more

    Symtuza: Uses, side effects, alternatives, and more - Medical News Today

    Image
    The Food and Drug Administration (FDA) approves prescription drugs such as Symtuza to treat certain conditions. Symtuza is FDA-approved to treat HIV-1 in adults and children who weigh at least 40 kilograms (kg), which is about 88 pounds (lb). It's approved for people who: have just been diagnosed with HIV and haven't started treatment yet, OR are changing from another HIV treatment and: have been on a stable antiretroviral regimen for at least 6 months (this means you haven't had any changes to your HIV drugs for at least 6 months) have a viral load (the amount of HIV in your blood) that's less than 50 copies per milliliter (mL) have HIV that doesn't have mutations (changes) that could make it resistant (less likely to respond) to darunavir or tenofovir (two of the active drugs in Symtuza) HIV explained HIV stands for human immunodeficiency virus. There are two forms of this virus, HIV-1 and HIV-2. HIV-1 is the most common form. HIV is transmitted through body fluid
    Read more